5 Takeaways For Payers From The TrumpRx Launch

What Does TrumpRx Mean For Payers?

Key Points

• TrumpRx launched February 5, 2026, offering cash-pay pricing for 43 drugs outside of insurance, with no eligibility for Medicare, Medicaid, or commercial reimbursement.
• The initial drug list has limited utilization impact today, representing about 2.3 percent of pharmacy claims according to PSG book-of-business, but increases pricing transparency for members.
• The most meaningful member impact comes from deep discounts on GLP-1 weight loss and infertility drugs, particularly for those without coverage or with high out-of-pocket exposure.
• Many TrumpRx drugs already have lower-cost generics available through insurance or existing discount programs, which may create member confusion.
• For payers, the launch signals growing pressure on PBM transparency, increased discount card utilization and accumulator considerations, and an expected expansion of direct-to‑consumer cash pay pricing.

The Trump Administration’s prescription drug pricing website officially launched on February 5th, 2026 after much fanfare and debate. The website is officially dubbed “TrumpRx,” and connects patients to cash-pay prescription drug options through a discount card program or direct-to-manufacturer for 43 drugs across multiple therapeutic categories. Most notably, the program exists outside of insurance, and drugs purchased through TrumpRx are not eligible for reimbursement through Medicare, Medicaid, or Commercial coverage. While the impact of the initial launch drugs is minimal (accounting for only 2.3% of pharmacy claims utilization over the most recent 12 months in PSG’s book of business), increased pricing transparency and accessibility for members represent incremental progress in the drug pricing landscape.

What are some of the takeaways for payers from the TrumpRx launch?

There are many potential threads to explore following the TrumpRx launch. To help payers navigate early questions from members and internal stakeholders, we have consolidated what we believe are the five most important takeaways from the initial rollout. If you would like to discuss additional aspects of the launch, we would be happy to connect. Please reach out using the contact form to start the conversation.

1. Net Pricing for Weight Loss GLP-1 Goes Mainstream

TrumpRx aims to bring transparent net pricing to patients seeking GLP-1 treatment for obesity. Wegovy and Zepbound, both currently with a list price over $1,000 per month prior to any application of manufacturer rebates, have TrumpRx costs ranging from $299-$449 depending on product and dose form. Members can obtain Zepbound vials through Lilly Direct or through their retail dispensing partner, Wal-Mart. Wegovy can be purchased at the TrumpRx price through any participating retail pharmacy partner.

Net pricing for GLP-1s represents a meaningful benefit for members in high-deductible health plans who must pay list price before cost sharing applies, as well as for many members who currently lack GLP-1 coverage. Payers should request greater transparency from their PBMs on current net pricing, reassess their existing coverage strategy, and explore how the PBM can incorporate the discount card price into the pharmacy benefit.

2. Real Savings for Infertility Drugs

Arguably the most impactful aspect of the TrumpRx program is the favorable pricing negotiated for four top infertility drugs manufactured by EMD Serono, with discounts up to 84% off the current list price. The four fertility drugs currently on the TrumpRx website (Cetrotide, Gonal-F, Gonal-F Redi-Ject, and Ovidrel) represent nearly 25% of all infertility drugs dispensed, per PSG’s book-of-business.

This pricing represents real progress for those in family planning stages and seeking infertility treatment. Infertility treatment is often excluded by payers, and even if payers provide coverage, there can be a lifetime coverage dollar limit. Members seeking infertility treatment are burdened with many other costs besides the drugs which contribute to the accumulation of the lifetime coverage limit, and favorable pricing will assist members in allocating those dollars elsewhere.

Payers must assess current infertility coverage, as these drugs, if covered, may be billed through either the pharmacy or the medical benefit depending on plan design. Many payers contract with a third-party point solution to manage fertility coverage (e.g., Progyny, Maven, Carrot) and will need to ensure that members seeking treatment are given options to access preferred pricing.

3. Many Brands with Generics Available

While the initial launch of the TrumpRx website contains 43 unique branded drugs, 13 of these have cheaper generic equivalents currently on the market. Payers should promote the use of generic medications whenever possible, as these options typically offer lower prices through PBM-negotiated rates and popular discount card programs such as GoodRx and Mark Cuban Cost Plus.  Moreover, it will be challenging for members to locate a retail pharmacy that stocks these older, branded products. This will add a layer of confusion and frustration to members seeking TrumpRx discount products and pricing.

Payers should review their current drug utilization data to determine if any members are using one of these branded products. Many are excluded standardly from the PBM’s template formulary or part of a “member-pay-the-difference” penalty program. However, branded drugs like Protonix, Levoxyl, Pristiq, and Cytomel may still be preferred by members hesitant to switch to a generic and may benefit from TrumpRx negotiated pricing.

4. The Rise of the Cash Discount Card and Accumulator Impact

While Trump Rx was initially touted as a direct-to-consumer model, the rollout from the website leans heavily on existing discount card infrastructure that primarily leverages GoodRx to process the claims. Out of the 43 launch drugs, 38 are backed by GoodRx or PDMI discount cards. PBMs have spent the last several years integrating GoodRx and other discount cards within the pharmacy benefit for generic drugs, though it remains to be seen how PBMs will integrate preferred GLP-1 and infertility discount pricing.

With over half of Americans enrolled in a high-deductible insurance plan, the impact to accumulators continues to be a point of discussion and potential confusion. Many of the drugs on the TrumpRx website state in the terms and conditions that “Patients enrolled in commercial insurance plans may not submit any claims for reimbursement for prescriptions purchased as part of this Program,” however, it leaves the impact to accumulators up to the payer in most cases.

Payers must work with compliance teams and PBM partners to determine if any of the drugs covered and paid for by members through the Trump Rx program may be applied to deductibles or maximum out-of-pocket costs.

5. Is There More to Come for TrumpRx?

Throughout 2025, many manufacturers announced direct-to-consumer pricing offers as mandated by the current administration, however, many of these drugs and manufacturers were notably missing from the initial rollout. Pfizer, EMD Serono, Eli Lilly, Novo Nordisk, and Astra Zeneca’s portfolios are prominently featured today, but more are expected. Bristol Myers Squibb announced a direct-to-consumer pricing model for Eliquis and Sotyktu, Amgen has announced a DTC offering for Aimovig, Amjevita, and Repatha, Gilead has announced for Epclusa and Xofluza, and Novartis has announced a DTC offering for Cosentyx.

Much of the criticism thus far is that many of these drugs remain unaffordable for most Americans (especially the high-cost specialty drugs) and that patients will still be reliant on insurance or third-party payment to afford treatment. Nonetheless, the transparency of net pricing at the pharmacy counter will allow payers and members easier data access to make informed decisions on the best price available in the market.

Closing Thoughts on the TrumpRx Launch

Ultimately, the launch of TrumpRx marks another inflection point in the evolving drug pricing landscape. Not because it immediately transforms payer economics, but because it accelerates the shift toward visible net pricing and manufacturer-to-patient distribution models.

For payers, the strategic question is less about the 43 drugs available today and more about what this signals for tomorrow: greater member awareness of cash options, increased scrutiny of PBM net pricing, potential disruption to accumulator programs, and a continued blurring of lines between insured and uninsured channels. As additional manufacturers expand direct-to-consumer offerings, payers will need to proactively evaluate coverage strategy, member communications, and contracting alignment.

Whether TrumpRx becomes a durable alternative channel or remains a political transparency tool, it reinforces a core reality. Pricing visibility is increasing, and stakeholders who fail to adapt will risk being reactive rather than strategic in the next phase of pharmacy benefit evolution.

If you would like to learn more about the impacts of TrumpRx on your plan, reach out to our pharmacy benefit experts!

Share on: